| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 97C5T2UQ7J |
| InChI Key | HVYWMOMLDIMFJA-DPAQBDIFSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C27H46O |
| Molecular Weight | 386.66 |
| AlogP | 7.39 |
| Hydrogen Bond Acceptor | 1.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 20.23 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 28.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Voltage-gated ion channel
Voltage-gated sodium channel
|
- | - | - | - | 3 | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group F
Nuclear hormone receptor subfamily 1 group F member 3
|
20-418 | - | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 100 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Asperger Syndrome | 1 | D020817 | ClinicalTrials |
| Autistic Disorder | 1 | D001321 | ClinicalTrials |
| Head and Neck Neoplasms | 1 | D006258 | ClinicalTrials |
| Smith-Lemli-Opitz Syndrome | 1 | D019082 | ClinicalTrials |
| Porokeratosis | 1 | D017499 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 57-88-5 |
| ChEBI | 16113 |
| ChEMBL | CHEMBL112570 |
| DrugBank | DB04540 |
| EPA CompTox | DTXSID3022401 |
| FDA SRS | 97C5T2UQ7J |
| Human Metabolome Database | HMDB0000067 |
| Guide to Pharmacology | 2718 |
| KEGG | C00187 |
| PDB | CLR |
| PubChem | 5997 |
| SureChEMBL | SCHEMBL2156 |
| ZINC | ZINC000003875383 |